Oscar Health (OSCR)
Market Price (9/25/2026): $28.82 | Market Cap: $8.7 BilSector: Health Care | Industry: Managed Health Care
Oscar Health (OSCR)
Market Price (9/25/2026): $28.82Market Cap: $8.7 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.3%, FCF Yield is 50% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -93% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 43% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 29%, CFO LTM is 4.4 Bil, FCF LTM is 4.4 Bil Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Health Data Analytics, and AI in Healthcare Management. | Weak multi-year price returns2Y Excs Rtn is -11% | Stock price has recently run up significantly6M Rtn6 month market price return is 144% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 122% Key risksOSCR key risks include [1] its ongoing challenge to achieve sustained profitability and manage costs and [2] its ability to successfully execute its growth strategy, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.3%, FCF Yield is 50% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -93% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 43% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 29%, CFO LTM is 4.4 Bil, FCF LTM is 4.4 Bil |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Health Data Analytics, and AI in Healthcare Management. |
| Weak multi-year price returns2Y Excs Rtn is -11% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 144% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 122% |
| Key risksOSCR key risks include [1] its ongoing challenge to achieve sustained profitability and manage costs and [2] its ability to successfully execute its growth strategy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/24/2026
Oscar Health (OSCR) stock has gained about 30% since 5/31/2026 because of the following key factors:
1. Oscar Health exceeded expectations with its fiscal Q2 2026 earnings and significantly raised its full-year guidance.
Oscar Health reported its fiscal Q2 2026 financial results on August 6, 2026, posting diluted earnings per share (EPS) of $1.10, which substantially surpassed analysts' consensus estimates ranging from $0.32 to $0.40 per share. This represented a 243.75% beat over the $0.32 estimate. The company's quarterly revenue also saw a significant increase of 70.4% year-over-year, reaching $4.88 billion, exceeding analyst expectations of $4.73 billion. A key factor in this performance was the substantial improvement in the Medical Loss Ratio (MLR), which decreased to 79.2% in fiscal Q2 2026 from 91.1% in the prior year, primarily due to disciplined pricing and $164 million of favorable prior-period reserve development. Following these strong results, Oscar Health raised its full-year 2026 earnings from operations guidance to a range of $500 million to $700 million, a $250 million increase at the midpoint from its previous outlook, and also lowered its full-year MLR guidance.
2. Analysts responded with positive rating adjustments and increased price targets following strong financial performance and a strategic Investor Day.
Positive analyst sentiment played a role in the stock's trend, with Barclays upgrading Oscar Health (OSCR) to "Overweight" from "Equal Weight" on June 10, 2026, and raising its price target from $30.00 to $35.00. This upgrade was attributed to a perceived valuation gap compared to peers within the Affordable Care Act (ACA) marketplace. Subsequently, after the release of the strong fiscal Q2 2026 results and the company's Investor Day on September 16, 2026, several investment analysts further revised their outlook positively. For example, Raymond James Financial increased its price target from $34.00 to $42.00, Barclays raised its target to $49, and Baird adjusted its target to $33. The average 12-month analyst price target for Oscar Health reached $33.90, with a high estimate of $49.00.
Show more
Oscar Health (OSCR) stock has gained about 30% since 5/31/2026 because of the following key factors:
1. Oscar Health exceeded expectations with its fiscal Q2 2026 earnings and significantly raised its full-year guidance.
Oscar Health reported its fiscal Q2 2026 financial results on August 6, 2026, posting diluted earnings per share (EPS) of $1.10, which substantially surpassed analysts' consensus estimates ranging from $0.32 to $0.40 per share. This represented a 243.75% beat over the $0.32 estimate. The company's quarterly revenue also saw a significant increase of 70.4% year-over-year, reaching $4.88 billion, exceeding analyst expectations of $4.73 billion. A key factor in this performance was the substantial improvement in the Medical Loss Ratio (MLR), which decreased to 79.2% in fiscal Q2 2026 from 91.1% in the prior year, primarily due to disciplined pricing and $164 million of favorable prior-period reserve development. Following these strong results, Oscar Health raised its full-year 2026 earnings from operations guidance to a range of $500 million to $700 million, a $250 million increase at the midpoint from its previous outlook, and also lowered its full-year MLR guidance.
2. Analysts responded with positive rating adjustments and increased price targets following strong financial performance and a strategic Investor Day.
Positive analyst sentiment played a role in the stock's trend, with Barclays upgrading Oscar Health (OSCR) to "Overweight" from "Equal Weight" on June 10, 2026, and raising its price target from $30.00 to $35.00. This upgrade was attributed to a perceived valuation gap compared to peers within the Affordable Care Act (ACA) marketplace. Subsequently, after the release of the strong fiscal Q2 2026 results and the company's Investor Day on September 16, 2026, several investment analysts further revised their outlook positively. For example, Raymond James Financial increased its price target from $34.00 to $42.00, Barclays raised its target to $49, and Baird adjusted its target to $33. The average 12-month analyst price target for Oscar Health reached $33.90, with a high estimate of $49.00.
Show more
Updated on 9/24/2026
Oscar Health (OSCR) stock has gained about 30% since 5/31/2026 because of the following key factors:
1. Oscar Health exceeded expectations with its fiscal Q2 2026 earnings and significantly raised its full-year guidance.
Oscar Health reported its fiscal Q2 2026 financial results on August 6, 2026, posting diluted earnings per share (EPS) of $1.10, which substantially surpassed analysts' consensus estimates ranging from $0.32 to $0.40 per share. This represented a 243.75% beat over the $0.32 estimate. The company's quarterly revenue also saw a significant increase of 70.4% year-over-year, reaching $4.88 billion, exceeding analyst expectations of $4.73 billion. A key factor in this performance was the substantial improvement in the Medical Loss Ratio (MLR), which decreased to 79.2% in fiscal Q2 2026 from 91.1% in the prior year, primarily due to disciplined pricing and $164 million of favorable prior-period reserve development. Following these strong results, Oscar Health raised its full-year 2026 earnings from operations guidance to a range of $500 million to $700 million, a $250 million increase at the midpoint from its previous outlook, and also lowered its full-year MLR guidance.
2. Analysts responded with positive rating adjustments and increased price targets following strong financial performance and a strategic Investor Day.
Positive analyst sentiment played a role in the stock's trend, with Barclays upgrading Oscar Health (OSCR) to "Overweight" from "Equal Weight" on June 10, 2026, and raising its price target from $30.00 to $35.00. This upgrade was attributed to a perceived valuation gap compared to peers within the Affordable Care Act (ACA) marketplace. Subsequently, after the release of the strong fiscal Q2 2026 results and the company's Investor Day on September 16, 2026, several investment analysts further revised their outlook positively. For example, Raymond James Financial increased its price target from $34.00 to $42.00, Barclays raised its target to $49, and Baird adjusted its target to $33. The average 12-month analyst price target for Oscar Health reached $33.90, with a high estimate of $49.00.
3. The company announced plans for significant market expansion and showcased the success of its turnaround strategy at its Investor Day.
Oscar Health's Investor Day on September 16, 2026, served as a platform to unveil strategic initiatives for future growth and highlight its successful turnaround. The company announced plans to expand its individual and small business coverage to an additional 400-600 new counties by 2029, leveraging its renewed profitability. Management emphasized its proven ACA model and its technology-driven platform, including AI integration, to enhance efficiency and member experience, with the goal of becoming the leading consumer-preferred, AI-native individual market carrier. Oscar Health also reported achieving over $1 billion in net income for the first half of fiscal 2026, signaling a significant shift to sustained profitability. Furthermore, the company provided long-term financial commitments for 2029, including a revenue compound annual growth rate (CAGR) exceeding 20%, an operating margin of 5-7%, and over $4.00 in EPS.
4. A notable insider purchase transaction exceeded the $5 million threshold within the past six months.
Within the specified period, Oscar Health experienced a significant insider buying transaction. While numerous insider sales were reported, one individual insider purchase transaction for an estimated $11.9 million was recorded over the last six months. This substantial investment by an insider indicates a strong belief in the company's future prospects and contributes to positive investor sentiment.
Show less
Oscar Health (OSCR) stock has gained about 30% since 5/31/2026 because of the following key factors:
1. Oscar Health exceeded expectations with its fiscal Q2 2026 earnings and significantly raised its full-year guidance.
Oscar Health reported its fiscal Q2 2026 financial results on August 6, 2026, posting diluted earnings per share (EPS) of $1.10, which substantially surpassed analysts' consensus estimates ranging from $0.32 to $0.40 per share. This represented a 243.75% beat over the $0.32 estimate. The company's quarterly revenue also saw a significant increase of 70.4% year-over-year, reaching $4.88 billion, exceeding analyst expectations of $4.73 billion. A key factor in this performance was the substantial improvement in the Medical Loss Ratio (MLR), which decreased to 79.2% in fiscal Q2 2026 from 91.1% in the prior year, primarily due to disciplined pricing and $164 million of favorable prior-period reserve development. Following these strong results, Oscar Health raised its full-year 2026 earnings from operations guidance to a range of $500 million to $700 million, a $250 million increase at the midpoint from its previous outlook, and also lowered its full-year MLR guidance.
2. Analysts responded with positive rating adjustments and increased price targets following strong financial performance and a strategic Investor Day.
Positive analyst sentiment played a role in the stock's trend, with Barclays upgrading Oscar Health (OSCR) to "Overweight" from "Equal Weight" on June 10, 2026, and raising its price target from $30.00 to $35.00. This upgrade was attributed to a perceived valuation gap compared to peers within the Affordable Care Act (ACA) marketplace. Subsequently, after the release of the strong fiscal Q2 2026 results and the company's Investor Day on September 16, 2026, several investment analysts further revised their outlook positively. For example, Raymond James Financial increased its price target from $34.00 to $42.00, Barclays raised its target to $49, and Baird adjusted its target to $33. The average 12-month analyst price target for Oscar Health reached $33.90, with a high estimate of $49.00.
3. The company announced plans for significant market expansion and showcased the success of its turnaround strategy at its Investor Day.
Oscar Health's Investor Day on September 16, 2026, served as a platform to unveil strategic initiatives for future growth and highlight its successful turnaround. The company announced plans to expand its individual and small business coverage to an additional 400-600 new counties by 2029, leveraging its renewed profitability. Management emphasized its proven ACA model and its technology-driven platform, including AI integration, to enhance efficiency and member experience, with the goal of becoming the leading consumer-preferred, AI-native individual market carrier. Oscar Health also reported achieving over $1 billion in net income for the first half of fiscal 2026, signaling a significant shift to sustained profitability. Furthermore, the company provided long-term financial commitments for 2029, including a revenue compound annual growth rate (CAGR) exceeding 20%, an operating margin of 5-7%, and over $4.00 in EPS.
4. A notable insider purchase transaction exceeded the $5 million threshold within the past six months.
Within the specified period, Oscar Health experienced a significant insider buying transaction. While numerous insider sales were reported, one individual insider purchase transaction for an estimated $11.9 million was recorded over the last six months. This substantial investment by an insider indicates a strong belief in the company's future prospects and contributes to positive investor sentiment.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 29.9% change in OSCR stock from 5/31/2026 to 9/24/2026 was primarily driven by a 15.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312026 | 9242026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.23 | 28.87 | 29.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13,302 | 15,319 | 15.2% |
| P/S Multiple | 0.5 | 0.6 | 14.3% |
| Shares Outstanding (Mil) | 298 | 302 | -1.3% |
| Cumulative Contribution | 29.9% |
Market Drivers
5/31/2026 to 9/24/2026| Return | Correlation | |
|---|---|---|
| OSCR | 29.9% | |
| Market (SPY) | 1.7% | 5.6% |
| Sector (XLV) | 14.1% | 26.1% |
Fundamental Drivers
The 111.7% change in OSCR stock from 2/28/2026 to 9/24/2026 was primarily driven by a 72.5% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9242026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.64 | 28.87 | 111.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11,701 | 15,319 | 30.9% |
| P/S Multiple | 0.3 | 0.6 | 72.5% |
| Shares Outstanding (Mil) | 283 | 302 | -6.3% |
| Cumulative Contribution | 111.7% |
Market Drivers
2/28/2026 to 9/24/2026| Return | Correlation | |
|---|---|---|
| OSCR | 111.7% | |
| Market (SPY) | 12.4% | 24.7% |
| Sector (XLV) | 6.9% | 30.4% |
Fundamental Drivers
The 73.3% change in OSCR stock from 8/31/2025 to 9/24/2026 was primarily driven by a 43.5% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9242026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.66 | 28.87 | 73.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10,727 | 15,319 | 42.8% |
| P/S Multiple | 0.4 | 0.6 | 43.5% |
| Shares Outstanding (Mil) | 256 | 302 | -15.4% |
| Cumulative Contribution | 73.3% |
Market Drivers
8/31/2025 to 9/24/2026| Return | Correlation | |
|---|---|---|
| OSCR | 73.3% | |
| Market (SPY) | 20.3% | 25.9% |
| Sector (XLV) | 25.8% | 18.7% |
Fundamental Drivers
The 360.4% change in OSCR stock from 8/31/2023 to 9/24/2026 was primarily driven by a 203.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9242026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.27 | 28.87 | 360.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5,048 | 15,319 | 203.5% |
| P/S Multiple | 0.3 | 0.6 | 109.0% |
| Shares Outstanding (Mil) | 219 | 302 | -27.4% |
| Cumulative Contribution | 360.4% |
Market Drivers
8/31/2023 to 9/24/2026| Return | Correlation | |
|---|---|---|
| OSCR | 360.4% | |
| Market (SPY) | 76.8% | 25.0% |
| Sector (XLV) | 34.1% | 21.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OSCR Return | -77% | -69% | 272% | 47% | 7% | 112% | -12% |
| Peers Return | 38% | 7% | -3% | -21% | -21% | 27% | 13% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| OSCR Win Rate | 20% | 33% | 67% | 67% | 42% | 56% | |
| Peers Win Rate | 57% | 52% | 47% | 45% | 52% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| OSCR Max Drawdown | - | -79% | -50% | -43% | -42% | -39% | |
| Peers Max Drawdown | -16% | -21% | -20% | -34% | -50% | -34% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: UNH, HUM, CNC, MOH, ELV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/24/2026 (YTD)
How Low Can It Go
| Event | OSCR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -27.5% | -18.8% |
| % Gain to Breakeven | 37.8% | 23.1% |
| Time to Breakeven | 15 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.3% | -9.5% |
| % Gain to Breakeven | 64.7% | 10.5% |
| Time to Breakeven | 25 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.5% | -6.7% |
| % Gain to Breakeven | 57.4% | 7.1% |
| Time to Breakeven | 4 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -57.6% | -24.5% |
| % Gain to Breakeven | 135.7% | 32.4% |
| Time to Breakeven | 224 days | 427 days |
In The Past
Oscar Health's stock fell -27.5% during the 2025 US Tariff Shock. Such a loss loss requires a 37.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | OSCR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -27.5% | -18.8% |
| % Gain to Breakeven | 37.8% | 23.1% |
| Time to Breakeven | 15 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.3% | -9.5% |
| % Gain to Breakeven | 64.7% | 10.5% |
| Time to Breakeven | 25 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.5% | -6.7% |
| % Gain to Breakeven | 57.4% | 7.1% |
| Time to Breakeven | 4 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -57.6% | -24.5% |
| % Gain to Breakeven | 135.7% | 32.4% |
| Time to Breakeven | 224 days | 427 days |
In The Past
Oscar Health's stock fell -27.5% during the 2025 US Tariff Shock. Such a loss loss requires a 37.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Oscar Health (OSCR)
Oscar Health, Inc. (OSCR) is a U.S.-based health insurance provider focused on offering a range of health insurance plans and related services. The company's primary offerings include health coverage for individuals and families through its Individual & Family plans, as well as Small Group plans designed for small businesses and their employees. Additionally, Oscar Health provides Medicare Advantage plans, catering to seniors and other eligible beneficiaries in the Medicare market.
Beyond its insurance products, Oscar Health distinguishes itself with +Oscar, a proprietary technology platform. This platform is utilized by healthcare providers and other payor clients to improve member and patient engagement, reflecting the company's tech-driven approach to healthcare. Oscar Health also diversifies its offerings by providing reinsurance products. Together, these services position Oscar Health as a multifaceted player in the U.S. health insurance and health technology landscape, serving a broad spectrum of consumers and industry clients.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Oscar Health:
- Like a Lemonade for health insurance.
- A tech-driven UnitedHealth Group.
AI Analysis | Feedback
- Individual & Family Health Insurance Plans: These plans offer health insurance coverage tailored for individuals and families in the United States.
- Small Group Health Insurance Plans: Oscar Health provides health insurance solutions specifically designed for small businesses and their employees.
- Medicare Advantage Plans: The company offers Medicare Advantage plans, which are health insurance options for eligible seniors as an alternative to original Medicare.
- +Oscar Platform: This is a technology-driven platform designed to help healthcare providers and payor clients engage more effectively with their members and patients.
- Reinsurance Products: Oscar Health also offers reinsurance products, which provide financial protection to other insurance companies against large or numerous claims.
AI Analysis | Feedback
Oscar Health's Major Customers
Oscar Health primarily serves individuals and small businesses, providing health insurance plans tailored to different segments of the population. Based on its core offerings, its major customer categories include:
- Individual Consumers and Families: Individuals who directly purchase health insurance plans for themselves and their families, often through the Affordable Care Act (ACA) marketplace.
- Seniors and Medicare-eligible Individuals: Individuals who enroll in Oscar Health's Medicare Advantage plans to receive health coverage.
- Small Businesses (Employers): Companies that purchase small group health insurance plans from Oscar Health to provide health benefits to their employees.
AI Analysis | Feedback
Supplier Name: UnitedHealth Group
Symbol: UNH
AI Analysis | Feedback
```html
Mark Bertolini, Chief Executive Officer
Mark Bertolini was appointed CEO of Oscar Health in April 2023. He previously served as Co-Chief Executive Officer of Bridgewater Associates and as the Chairman and CEO of Aetna Inc. from 2010 to 2018. During his tenure at Aetna, he guided the company's transformation from a traditional health insurance provider to a consumer-centric healthcare company. Aetna was subsequently acquired by CVS Health in 2018. His career also includes executive roles at Cigna, NYLCare Health Plans, and SelectCare, Inc.
R. Scott Blackley, Chief Financial Officer
R. Scott Blackley has been Oscar Health's Chief Financial Officer since August 2023, having previously held the CFO position from March 2021 to December 2022 and serving as Chief Transformation Officer from December 2022 to August 2023. Before joining Oscar, he was the Chief Financial Officer of Capital One from May 2016 to March 2021. His extensive background in finance also includes various executive roles at Fannie Mae, including CFO of the Capital Markets Group, and prior positions at the U.S. Securities and Exchange Commission as a Professional Accounting Fellow, and as a Partner at KPMG, LLP.
Mario Schlosser, Co-Founder & President of Technology, Chief Technology Officer
Mario Schlosser co-founded Oscar Health in 2012 and previously served as its CEO, leading the company from its inception. In his current role, he oversees product and engineering, focusing on the development of Oscar's technology platform and guiding the strategy for +Oscar. Prior to Oscar, Schlosser co-founded the largest social gaming company in Latin America, where he was responsible for analytics and game design. He also held roles as a Senior Investment Associate at Bridgewater Associates and as a consultant at McKinsey & Company.
Ranmali Bopitiya, Chief Legal Officer
Ranmali Bopitiya joined Oscar Health as Chief Legal Officer, effective January 31, 2022, overseeing the company's legal, risk, and government affairs functions. Before Oscar, she served as Chief Legal Officer at Everside Health and as Vice President and General Counsel for Colorado Permanente Medical Group of Kaiser Permanente. She also led the legal function for a high-growth startup within Stanford Health Care.
Steve Wolin, Chief Operating Officer
Steve Wolin joined Oscar Health in 2020 and is responsible for leading the development and execution of Oscar's service organization, insurance operations, population health, pharmacy services, behavioral health, and virtual care. Before his time at Oscar, Wolin was the head of corporate strategy and strategic partnership for Optum.
```AI Analysis | Feedback
The key risks to Oscar Health (OSCR) are:
- High Medical Loss Ratio (MLR) and Path to Profitability: Oscar Health consistently faces challenges in translating revenue growth into sustainable profit due to a high Medical Loss Ratio (MLR), which represents the percentage of premium revenue spent on medical claims. For the 2025 fiscal year, the company projects its MLR to be between 86.0% and 87.0%, leading to an anticipated operating loss between $200 million and $300 million. This is exacerbated by increased market morbidity, meaning a higher proportion of sicker individuals are entering their risk pool. The company's ability to accurately price its plans and effectively manage healthcare costs for its members is crucial for achieving profitability.
- Expiration of Enhanced Federal Subsidies and ACA Marketplace Competition: A significant macro-economic risk for Oscar Health is the potential expiration of enhanced federal subsidies within the Affordable Care Act (ACA) marketplace. This could lead to a contraction in the individual health insurance market, resulting in margin compression and a decrease in membership for Oscar Health. The company has acknowledged this risk, pricing for a potential 20-30% market shrinkage. Additionally, increased competition from larger insurers in the ACA marketplace poses a challenge to Oscar Health's growth and member retention.
- Reliance on Reinsurance and Regulatory Capital Requirements: Oscar Health relies on quota share reinsurance arrangements to meet regulatory capital and surplus requirements and to mitigate the financial risk associated with medical claims. A significant risk is the potential inability to renew these reinsurance agreements on favorable terms or to obtain regulatory approval for them, which could adversely impact Oscar Health's capital position and its compliance with regulatory obligations. Furthermore, as Oscar Health expands its member base and enters new markets, it is required to contribute additional capital to its insurance subsidiaries to meet capital and surplus requirements, which can be substantial and potentially exceed the net income generated by these new ventures.
AI Analysis | Feedback
The increasing strategic moves and investments by major technology companies (e.g., Amazon, Google, Apple) into direct healthcare delivery and potential health plan offerings, which could leverage their superior data, technology, and consumer engagement capabilities to disrupt the health insurance market, particularly impacting tech-centric insurers like Oscar Health.
AI Analysis | Feedback
Oscar Health (OSCR) operates within significant addressable markets in the United States for its main products and services.
Here are the identified addressable market sizes:
- Individual & Family Plans: The U.S. individual health insurance market was valued at approximately USD 1.60 trillion in 2022 and is projected to reach around USD 2.54 trillion by 2030. Oscar Health is a key player in this segment, particularly within the Affordable Care Act (ACA) market, which had 21 million members as of 2021, with projections to climb to 24 million or even 31 million members if enhanced subsidies are extended.
- Small Group (shifting to Individual Coverage Health Reimbursement Arrangements - ICHRAs): While Oscar Health ceased offering traditional small group policies as of December 2024, the company is strategically targeting the Individual Coverage Health Reimbursement Arrangement (ICHRA) market. If all employers with fewer than 1,000 employees adopted ICHRAs, Oscar Health's addressable market for this offering could expand from 21 million to 96 million lives in the U.S. For context, the broader U.S. group health insurance market was estimated at USD 1.41 trillion in 2024.
- +Oscar (Technology Platform): For its technology-driven platform, +Oscar, the addressable market is within the healthcare payer technology solutions sector. The technology solutions in the U.S. healthcare payer market was estimated at approximately USD 7.8 billion in 2023 and is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 7.3% from 2024 to 2030. Another source valued this market at USD 7.6 billion in 2023, expecting growth to USD 14.1 billion by 2032.
- Reinsurance Products: Oscar Health utilizes reinsurance arrangements as part of its operations. The U.S. reinsurance market size was valued at USD 220.05 billion in 2024 and is projected to reach USD 630.10 billion by 2034, demonstrating a CAGR of 11.09% from 2025 to 2034.
AI Analysis | Feedback
Oscar Health (OSCR) anticipates several key drivers for its future revenue growth over the next two to three years:
- Membership Growth: Oscar Health has achieved significant growth in its member base, reaching approximately 3.4 million members as of February 1, 2026, a substantial increase from previous years. This growth is a primary factor in the company's projected total revenues of $18.7 billion to $19 billion for 2026, representing a 61% year-over-year increase at the midpoint. The introduction of a new suite of affordable products and an exceptional member experience contributed to this record membership.
- Pricing Discipline and Rate Increases: The company has implemented strategic pricing adjustments, including a weighted average rate increase of approximately 28% for 2026. These rate increases are a direct contributor to higher revenue per member.
- Market Share Expansion: Oscar Health has expanded its market share across its operational footprint, growing from 17% in 2025 to 30% in 2026. This increase in market share, partly driven by competitors such as CVS Health exiting the individual Affordable Care Act (ACA) exchange market, leads to a larger customer base and, consequently, higher revenue.
- AI-driven Efficiency and Technology Platform (+Oscar): Oscar Health leverages its proprietary technology platform, including "Agentic AI features" and "Oswell," an AI-driven health agent, to enhance member experience and operational efficiency. While these advancements are crucial for improving profitability by reducing the medical loss ratio and SG&A expenses, they also indirectly fuel revenue growth by enabling competitive product offerings and superior engagement, which drive membership acquisition and retention. The company's technology is designed to deliver superior experiences, deep engagement, and high-value clinical care.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Repurchases
- Oscar Health has not made any share repurchases over the last 3-5 years, with historical data showing $0.00 in share buybacks.
Share Issuance
- Oscar Health completed its Initial Public Offering (IPO) in March 2021, offering 37,041,026 shares of Class A common stock at $39.00 per share.
- The company itself sold 36,391,946 shares during the IPO, raising approximately $1.4446 billion.
- Share issuances have continued in subsequent years, contributing to an increase in shares outstanding from 174.40 million in 2021 to 255.42 million in 2025.
Inbound Investments
- Prior to its IPO, Google's parent company, Alphabet Inc., was a significant shareholder with approximately an 18% ownership stake.
- Fidelity and Alphabet were among its largest investors, contributing $400 million and $375 million, respectively, in earlier funding rounds.
- Institutional ownership includes major firms such as Vanguard Group Inc, BlackRock, Inc., Morgan Stanley, and Thrive Capital Management, LLC, holding a substantial number of shares.
Capital Expenditures
- Capital expenditures were reported as $6.8 million in December 2024.
- Quarterly capital expenditures for 2025 were $9.0 million (March 31), $9.3 million (June 30), and $9.0 million (September 30).
- A primary focus of these expenditures is investments in physical assets and its technology-driven platform, "+Oscar," which is integral to its business model.
Peer Outperformance in Managed Health Care
OSCR has outperformed 100% of its 7 Managed Health Care peers over 5Y. Managed Health Care ranks 3rd of 10 industries in Health Care by median 5Y return. That makes it one of the strongest corners of the sector.
Share of Managed Health Care constituents that OSCR has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
86%
of 7 industry peers · 56.6% return
3Y
100%
of 7 industry peers · 418.3% return
5Y
100%
of 7 industry peers · 70.0% return
No Managed Health Care peer with a comparable growth profile has beaten OSCR by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Managed Health Care is OSCR's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 8.0% | 42.8% | 88.3% | CAH 385% · MCK 339% · COR 167% |
| Health Care Services | 20 | 18.6% | 31.5% | 3.3% | HIMS 261% · RDNT 144% · DGX 70% |
| Managed Health Care ← | 8 | 32.3% | -10.0% | 0.5% | OSCR 70% · HQY 34% · ELV 12% |
| Health Care Facilities | 24 | 1.9% | 6.9% | -4.8% | NHC 266% · THC 250% · ENSG 132% |
| Health Care Equipment | 50 | -3.5% | -2.2% | -19.2% | POCI 11838% · UFPT 380% · GKOS 206% |
| Health Care Supplies | 12 | 24.2% | -7.1% | -38.0% | LNTH 270% · HAE 53% · MMSI 21% |
| Pharmaceuticals | 62 | -9.1% | 4.5% | -42.3% | LQDA 2372% · INDV 1100% · ETON 1087% |
| Life Sciences Tools & Services | 113 | -0.4% | -10.9% | -67.1% | SNWV 1880% · NTRA 246% · MEDP 213% |
| Health Care Technology | 21 | -29.4% | -52.6% | -78.6% | SPOK 70% · HSTM 1% · VEEV -8% |
| Biotechnology | 379 | -8.4% | -21.6% | -79.3% | CELZ 1286% · DNTH 1114% · ELVN 975% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 284.16 |
| Mkt Cap | 38.1 |
| Rev LTM | 173,396 |
| Op Inc LTM | 1,616 |
| FCF LTM | 5,334 |
| FCF 3Y Avg | 3,021 |
| CFO LTM | 5,941 |
| CFO 3Y Avg | 3,395 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 11.1% |
| Rev Chg Q | 5.7% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | -29.5% |
| Op Inc Chg 3Y Avg | -20.9% |
| Op Mgn LTM | 0.8% |
| Op Mgn 3Y Avg | 2.9% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 4.3% |
| CFO/Rev 3Y Avg | 2.7% |
| FCF/Rev LTM | 3.8% |
| FCF/Rev 3Y Avg | 2.1% |
Price Behavior
Price Behavior
| Market Price | $28.87 | |
| Market Cap ($ Bil) | 8.7 | |
| First Trading Date | 03/03/2021 | |
| Distance from 52W High | -14.6% | |
| 50 Days | 200 Days | |
| DMA Price | $30.68 | $21.44 |
| DMA Trend | up | up |
| Distance from DMA | -5.9% | 34.6% |
| 3M | 1YR | |
| Volatility | 59.4% | 70.3% |
| Downside Capture | 114.62 | 115.23 |
| Upside Capture | 93.26 | 146.50 |
| Correlation (SPY) | 7.5% | 26.0% |
OSCR Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.76 | 0.94 | 0.28 | 1.24 | 1.48 | 1.20 |
| Up Beta | -2.22 | -1.00 | -0.59 | 1.32 | 1.31 | 0.77 |
| Down Beta | 0.73 | 0.30 | -1.13 | 0.86 | 1.95 | 1.11 |
| Up Capture | 174% | 150% | 195% | 266% | 206% | 651% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 9 | 18 | 30 | 67 | 119 | 355 |
| Down Capture | 380% | 231% | 42% | 55% | 107% | 107% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 12 | 24 | 34 | 60 | 132 | 389 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSCR | |
|---|---|---|---|---|
| OSCR | 62.9% | 70.2% | 0.97 | - |
| Sector ETF (XLV) | 25.8% | 16.2% | 1.23 | 19.0% |
| Equity (SPY) | 16.7% | 13.0% | 0.92 | 25.9% |
| Gold (GLD) | 13.1% | 29.3% | 0.42 | 9.4% |
| Commodities (DBC) | 45.1% | 20.7% | 1.71 | -3.4% |
| Real Estate (VNQ) | 3.7% | 13.7% | 0.01 | 22.5% |
| Bitcoin (BTCUSD) | -24.8% | 44.8% | -0.51 | 26.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSCR | |
|---|---|---|---|---|
| OSCR | 10.3% | 80.1% | 0.46 | - |
| Sector ETF (XLV) | 6.8% | 15.2% | 0.26 | 24.4% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 32.7% |
| Gold (GLD) | 19.0% | 18.8% | 0.82 | 6.4% |
| Commodities (DBC) | 10.6% | 19.6% | 0.42 | 6.6% |
| Real Estate (VNQ) | 0.7% | 18.9% | -0.07 | 30.4% |
| Bitcoin (BTCUSD) | 12.0% | 52.6% | 0.41 | 18.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSCR | |
|---|---|---|---|---|
| OSCR | -2.0% | 79.0% | 0.29 | - |
| Sector ETF (XLV) | 10.9% | 16.7% | 0.53 | 22.9% |
| Equity (SPY) | 15.5% | 17.9% | 0.73 | 31.3% |
| Gold (GLD) | 12.0% | 16.4% | 0.60 | 6.8% |
| Commodities (DBC) | 8.5% | 18.1% | 0.39 | 6.6% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.19 | 29.2% |
| Bitcoin (BTCUSD) | 63.7% | 66.2% | 1.03 | 17.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | -11.9% | -1.7% | 7.1% |
| 5/6/2026 | 10.6% | 32.3% | 31.5% |
| 2/10/2026 | 1.7% | 5.8% | 5.8% |
| 11/6/2025 | -2.8% | -11.3% | -1.8% |
| 8/6/2025 | 3.8% | 8.4% | 33.0% |
| 5/7/2025 | 30.2% | 29.5% | 19.7% |
| 2/4/2025 | 3.1% | -7.7% | 2.2% |
| 11/7/2024 | -12.3% | -13.3% | 0.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 16 |
| # Negative | 8 | 9 | 6 |
| Median Positive | 11.2% | 18.9% | 9.1% |
| Median Negative | -7.9% | -7.7% | -9.2% |
| Max Positive | 30.3% | 47.6% | 42.9% |
| Max Negative | -24.5% | -29.2% | -34.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | -11.9% | -1.7% | 7.1% |
| 5/6/2026 | 10.6% | 32.3% | 31.5% |
| 2/10/2026 | 1.7% | 5.8% | 5.8% |
| 11/6/2025 | -2.8% | -11.3% | -1.8% |
| 8/6/2025 | 3.8% | 8.4% | 33.0% |
| 5/7/2025 | 30.2% | 29.5% | 19.7% |
| 2/4/2025 | 3.1% | -7.7% | 2.2% |
| 11/7/2024 | -12.3% | -13.3% | 0.4% |
| 8/7/2024 | -3.1% | 6.1% | 1.0% |
| 5/7/2024 | 4.2% | 15.7% | 3.8% |
| 2/7/2024 | 24.4% | 26.0% | 9.1% |
| 11/7/2023 | 15.9% | 19.1% | 42.9% |
| 8/8/2023 | 12.1% | 6.0% | -7.6% |
| 5/9/2023 | -3.9% | -4.1% | 24.1% |
| 2/9/2023 | 30.3% | 47.6% | 2.6% |
| 11/8/2022 | -23.5% | -5.9% | -10.7% |
| 8/11/2022 | 19.2% | 18.9% | -2.9% |
| 5/10/2022 | -3.3% | -2.0% | -20.4% |
| 2/10/2022 | 4.4% | 9.5% | 9.2% |
| 11/10/2021 | -24.5% | -29.2% | -34.1% |
| 8/12/2021 | 0.3% | -11.8% | 16.7% |
| 5/13/2021 | 11.8% | 20.4% | 21.9% |
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 16 |
| # Negative | 8 | 9 | 6 |
| Median Positive | 11.2% | 18.9% | 9.1% |
| Median Negative | -7.9% | -7.7% | -9.2% |
| Max Positive | 30.3% | 47.6% | 42.9% |
| Max Negative | -24.5% | -29.2% | -34.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/07/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/13/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/15/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/07/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/13/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/15/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/13/2021 | 10-Q |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 03/04/2021 | 424B4 |
Insider Activity
Updated 9/22/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wittman, Vanessa Ames | Direct | Sell | 9222026 | 32.24 | 25,000 | 806,000 | 3,614,781 | Form | |
| 2 | Baltrus, Victoria | Chief Accounting Officer | Direct | Sell | 9082026 | 31.45 | 958 | 30,129 | 6,718,695 | Form |
| 3 | Liang, Janet | President, Oscar Insurance | Direct | Sell | 9082026 | 31.45 | 10,360 | 325,822 | 7,821,521 | Form |
| 4 | Blackley, Richard Scott | Chief Financial Officer | Direct | Sell | 9082026 | 31.45 | 28,869 | 907,930 | 32,900,097 | Form |
| 5 | McAnaney, Adam | Chief Legal Officer | Direct | Sell | 9082026 | 31.45 | 9,092 | 285,943 | 6,573,176 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wittman, Vanessa Ames | Direct | Sell | 9222026 | 32.24 | 25,000 | 806,000 | 3,614,781 | Form | |
| 2 | Baltrus, Victoria | Chief Accounting Officer | Direct | Sell | 9082026 | 31.45 | 958 | 30,129 | 6,718,695 | Form |
| 3 | Liang, Janet | President, Oscar Insurance | Direct | Sell | 9082026 | 31.45 | 10,360 | 325,822 | 7,821,521 | Form |
| 4 | Blackley, Richard Scott | Chief Financial Officer | Direct | Sell | 9082026 | 31.45 | 28,869 | 907,930 | 32,900,097 | Form |
| 5 | McAnaney, Adam | Chief Legal Officer | Direct | Sell | 9082026 | 31.45 | 9,092 | 285,943 | 6,573,176 | Form |
| 6 | Schlosser, Mario | Direct | Sell | 9082026 | 31.45 | 31,422 | 988,222 | 14,135,014 | Form | |
| 7 | Schlosser, Mario | Direct | Sell | 8312026 | 30.79 | 150,000 | 4,618,500 | 14,805,864 | Form | |
| 8 | Schlosser, Mario | Direct | Sell | 8312026 | 30.34 | 600,000 | 18,204,000 | 14,589,474 | Form | |
| 9 | Blackley, Richard Scott | Chief Financial Officer | MQB Irrevocable Trust | Sell | 8202026 | 31.74 | 18,750 | 595,125 | 1,785,375 | Form |
| 10 | Schlosser, Mario | Pizzo-Schlosser Family Dynasty Trust | Sell | 7062026 | 31.24 | 47,500 | Form | |||
| 11 | Bertolini, Mark T | Chief Executive Officer | Direct | Sell | 7012026 | 28.48 | 624,244 | 17,781,383 | 220,800,899 | Form |
| 12 | Bertolini, Mark T | Chief Executive Officer | Direct | Sell | 7012026 | 29.26 | 614,752 | 17,985,938 | 245,053,087 | Form |
| 13 | Bertolini, Mark T | Chief Executive Officer | Direct | Sell | 6292026 | 29.28 | 591,168 | 17,310,761 | 263,264,487 | Form |
| 14 | Bertolini, Mark T | Chief Executive Officer | Direct | Sell | 6292026 | 28.61 | 615,142 | 17,601,317 | 274,166,192 | Form |
| 15 | Schlosser, Mario | Direct | Sell | 6252026 | 29.38 | 880,000 | 25,850,515 | 14,125,720 | Form | |
| 16 | Schlosser, Mario | Noah Pizzo-Schlosser Dynasty Trust | Sell | 6252026 | 29.38 | 50,000 | Form | |||
| 17 | Schlosser, Mario | Siena Pizzo-Schlosser Dynasty Trust | Sell | 6252026 | 29.38 | 50,000 | Form | |||
| 18 | Schlosser, Mario | Pizzo-Schlosser Family Dynasty Trust | Sell | 6252026 | 29.38 | 47,500 | Form | |||
| 19 | Baltrus, Victoria | Chief Accounting Officer | Direct | Sell | 6042026 | 21.94 | 1,523 | 33,417 | 4,708,381 | Form |
| 20 | Schlosser, Mario | Direct | Sell | 6042026 | 21.94 | 34,120 | 748,633 | 10,550,768 | Form | |
| 21 | McAnaney, Adam | Chief Legal Officer | Direct | Sell | 6042026 | 21.94 | 9,859 | 216,318 | 4,785,290 | Form |
| 22 | Liang, Janet | President, Oscar Insurance | Direct | Sell | 6042026 | 21.94 | 12,475 | 273,716 | 5,684,019 | Form |
| 23 | Blackley, Richard Scott | Chief Financial Officer | Direct | Sell | 6042026 | 21.94 | 31,683 | 695,162 | 23,586,253 | Form |
| 24 | Blackley, Richard Scott | Chief Financial Officer | Direct | Sell | 5202026 | 25.03 | 110,000 | 2,753,300 | 27,699,700 | Form |
| 25 | Blackley, Richard Scott | Chief Financial Officer | Direct | Sell | 5182026 | 23.16 | 100,000 | 2,316,031 | 28,178,226 | Form |
| 26 | Bertolini, Mark T | Chief Executive Officer | Direct | Buy | 4072026 | 11.92 | 1,000,000 | 11,920,000 | 121,546,762 | Form |
| 27 | Liang, Janet | President, Oscar Insurance | Direct | Sell | 3042026 | 13.39 | 7,453 | 99,796 | 3,635,813 | Form |
| 28 | Baltrus, Victoria | Chief Accounting Officer | Direct | Sell | 3042026 | 13.39 | 4,638 | 62,103 | 2,893,740 | Form |
| 29 | McAnaney, Adam | Chief Legal Officer | Direct | Sell | 3042026 | 13.39 | 18,710 | 250,527 | 3,052,317 | Form |
| 30 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 3042026 | 13.39 | 24,335 | 325,846 | 6,895,663 | Form |
| 31 | Blackley, Richard Scott | Chief Financial Officer | Direct | Sell | 3042026 | 13.39 | 19,221 | 257,369 | 19,638,577 | Form |
| 32 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 1122026 | 17.65 | 23,038 | 406,621 | 6,180,677 | Form |
| 33 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 1062026 | 15.64 | 96,928 | 1,515,954 | 5,476,815 | Form |
| 34 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 1062026 | 15.02 | 137,933 | 2,071,754 | 5,410,429 | Form |
| 35 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 12302025 | 15.00 | 38,835 | 582,525 | 6,575,220 | Form |
| 36 | McAnaney, Adam | Chief Legal Officer | Direct | Sell | 12042025 | 16.59 | 1,852 | 30,725 | 2,973,608 | Form |
| 37 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 12042025 | 16.59 | 23,965 | 397,579 | 7,916,466 | Form |
| 38 | Liang, Janet | President, Oscar Insurance | Direct | Sell | 12042025 | 16.59 | 7,338 | 121,737 | 2,862,223 | Form |
| 39 | Blackley, Richard Scott | Chief Financial Officer | Direct | Sell | 12042025 | 16.59 | 25,135 | 416,990 | 22,413,654 | Form |
| 40 | Baltrus, Victoria | Chief Accounting Officer | Direct | Sell | 12042025 | 16.59 | 4,149 | 68,832 | 3,375,236 | Form |
| 41 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 11132025 | 15.05 | 105,300 | 1,584,765 | 7,542,277 | Form |
| 42 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 11132025 | 15.27 | 286,182 | 4,369,999 | 7,652,530 | Form |
| 43 | Schlosser, Mario | President of Technology & CTO | Direct | Sell | 9242025 | 18.43 | 395,000 | 7,279,850 | 9,236,158 | Form |
Investor Activity (13F)
Updated Sep 25, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
| Active Manager |
|---|
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/24/2026